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Abstract:  
Background. Designing trials to reduce treatment duration is important in several therapeutic 
areas, including TB and antibiotics. We recently proposed a new randomised trial design to 
overcome some of the limitations of standard two-arm non-inferiority trials. This 
DURATIONS design involves randomising patients to a number of duration arms, and 
modelling the so-called ‘duration-response curve’. This article investigates the operating 
characteristics (type-1 and type-2 errors) of different statistical methods of drawing inference 
from the estimated curve.  
Methods. Our first estimation target is the shortest duration non-inferior to the control 
(maximum) duration within a specific risk difference margin. We compare different methods 
of estimating this quantity, including using model confidence bands, the delta method and 
bootstrap. We then explore the generalisability of results to estimation targets which focus on 
absolute event rates, risk ratio and gradient of the curve. 
Results. We show through simulations that, in most scenarios and for most of the estimation 
targets, using the bootstrap to estimate variability around the target duration leads to good 
results for DURATIONS design-appropriate quantities analogous to power and type-1 error. 
Using model confidence bands is not recommended, while the delta method leads to inflated 
type-1 error in some scenarios, particularly when the optimal duration is very close to one of 
the randomised durations.  
Conclusions. Using the bootstrap to estimate the optimal duration in a DURATIONS design 
has good operating characteristics in a wide range of scenarios, and can be used with 
confidence by researchers wishing to design a DURATIONS trial to reduce treatment 
duration. Uncertainty around several different targets can be estimated with this bootstrap 
approach.  
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1. Introduction 
In several therapeutic areas, it is important to identify the optimal duration of treatment, 
defined as the shortest duration providing an acceptable efficacy. For example, reducing 
antibiotic treatment duration has been suggested as a way of combatting antimicrobial 
resistance1, but this has to be done while maintaining high cure rates. Furthermore, shorter 
treatment durations often increase adherence, reduce side-effects and will be more cost-
effective, provided they do not lead to an increased risk of relapse. 
 
We recently proposed the DURATIONS randomised trial design2 as an improvement over 
standard non-inferiority trials3 for identifying the shortest acceptable treatment duration4. Its 
main attraction is that it does not involve selection of a single shorter duration to test against 
a control, which is often chosen based on very limited prior evidence; instead, patients are 
randomised to multiple durations, enabling the relationship between duration and response to 
be directly estimated using pre-specified flexible regression models. Randomising 500 
patients to 5-7 durations enables the underlying duration-response curve to be estimated 
within 5% average absolute error in 95% of simulations2.  
 
The DURATIONS design moves away from a binary hypothesis testing paradigm, so that the 
trial outcome is not a treatment difference between two fixed durations, but rather the whole 
estimated duration-response curve. In applications, we wish to use this curve to inform 
decision-making, and hence it is essential to understand the properties of various ways of 
drawing inference from the curve. This article therefore first defines DURATION-design 
quantities analogous to power and type-I error, and then compares different strategies of 
inference for these quantities, through extensive simulations.  
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2. Drawing inference from the duration-response curve 
 
Suppose there is a treatment that is known to be highly effective compared to placebo, and 
that is usually prescribed as standard-of-care to patients with a particular disease or condition 
for a fixed course duration; examples include antibiotics for bacterial infections and direct 
acting antivirals against Hepatitis C. Additionally, suppose the recommended treatment 
course is 𝐷ெ஺௑ days, although we believe that shorter durations might be similarly effective, 
so that we suspect the shortest effective duration might be as small as 𝐷ெூே.  
 
Now, suppose we want to design a trial to identify the shortest effective duration and assume 
that the primary outcome of the trial is cure, a binary variable equal to 1 if the patient 
recovers from their condition or 0 otherwise. Using a DURATIONS randomised trial design2 
we randomise N, say 500, patients to multiple, e.g. 7, duration arms, between and including 
𝐷ெ஺௑ and 𝐷ெூே. After observing the responses, we fit a pre-specified fractional polynomial 
logistic model with cure as outcome and duration as the only covariate, with up to two 
polynomial terms. This gives us an estimated duration-response curve, similar to the black 
curve in Figure 1.  
 
When provided with this curve, how should clinicians and policy-makers choose what is the 
‘optimal’ duration to prescribe? A simple choice is to target the duration leading to at most a 
fixed risk loss of efficacy (difference 𝛿) compared to the control (maximum) duration, e.g. 
5% less. Hence, if the estimated control cure rate at 𝐷ெ஺௑ was 𝜋஽ಾಲ೉, our objective would be 
to find the minimum duration 𝐷∗ corresponding to a cure rate of at least 𝜋஽∗ = 𝜋஽ಾಲ೉ − 𝛿. 
The rationale for this choice closely corresponds to that for the choice of margin in non-
inferiority trials, i.e. it answers the question “what is the minimum treatment efficacy that we 
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would be happy to tolerate, given the ancillary advantages of the active treatment (i.e. of 
reducing treatment duration)”?  
 
In this section we propose different ways of estimating such a 𝐷∗ from the duration-response 
curve, and investigate their operating characteristics in Section 3. We extend to different 
possible objectives in Section 4.  
 
2.1. Model confidence bands 
The simplest approach is to extrapolate 𝐷∗ from the duration-response curve, selecting the 
duration at which 𝜋஽∗ = 𝜋஽ಾಲ೉ − 𝛿. However, the fitted curve is just the most likely 
estimated from the sample data. Thus, there is a non-negligible probability that the true 𝐷∗ is 
below this value. Instead, we will typically wish to keep type-1 error below 2.5%, so that we 
do not recommend a duration that is not long enough more than 2.5% of the time.  
 
The first and most naïve method of controlling type-1 error uses the lower bound of the 
pointwise confidence bands around the curve, looking for the duration 𝐷∗ satisfying 𝜋஽∗ −
1.96𝑆𝐸గವ∗ = 𝜋஽ಾಲ೉ − 𝛿. To avoid recommending non-integer durations, which might make 
little sense in applications, we round the selected duration 𝐷௅∗ up to the next whole number; 
hence, we select the duration 𝐷ூ that satisfies: 
𝐷ூ = min𝑫𝒊
( 𝐷௜ > 𝐷௅∗) 
With 𝑫𝒊 being the set of integer durations. 
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2.2. Delta method CI 
To compare two specific points on the duration-response curve, we need to estimate a 
confidence interval around the difference in outcome between the two points. In our 
application, we really want to compare each shorter duration 𝐷௜ against the longest duration 
𝐷ெ஺௑; hence, we want to estimate the confidence intervals around 𝜋஽ಾಲ೉ − 𝜋஽೔ for every 𝐷௜ 
(including any integer duration randomised to or not randomised to below 𝐷ெ஺௑). Let us call 
these confidence intervals 𝐶𝐼஽ಾಲ೉ି஽೔
ଵିఈ = ൫𝐶𝐼஽ಾಲ೉ି஽೔
௟ , 𝐶𝐼஽ಾಲ೉ି஽೔
௨ ൯, with 𝛼 being the confidence 
level. These can be estimated using the delta-method, which gives a good approximation 
based on Taylor series expansions (details in Appendix A). Inference can then be drawn by 
selecting the minimum duration 𝐷∗ for which 𝐶𝐼஽ಾಲ೉ି஽∗
௨ < 𝛿.  
 
2.3. Bootstrap CI  
Alternatively, rather than relying on these approximations, given the observed dataset with N 
observations we can sample with replacement N observations M times, generating M 
bootstrap samples. We then fit the fractional polynomial model on each of the M datasets and 
estimate in each bootstrap sample 𝜋஽ಾಲ೉ − 𝜋஽೔ for every 𝐷௜ . We then calculate bootstrap 
confidence intervals around these quantities, and use these to choose the optimal 𝐷∗. 
 
2.4. Bootstrap Duration CI 
 
Another way of using bootstrapping is to directly estimate a confidence interval around 𝐷∗. 
M bootstrap samples are selected similarly to Section 2.3, but instead of estimating 𝜋஽ಾಲ೉ −
𝜋஽೔ in each sample we estimate the corresponding 𝐷
∗, denoted 𝐷௠∗ , with m indexing the 
bootstrap sample. Then a bootstrap confidence interval (𝐷∗,௟, 𝐷∗,௨) can be constructed from 
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the bootstrap mean estimate 𝐷∗෢  and its standard error, and the recommended duration would 
be: 
𝐷ூ = min௜ ( 𝐷௜ > 𝐷
∗,௨) 
 
2.5. Theoretical comparison of methods 
 
Table 1 provides an overview of the properties of different methods. The attractiveness of the 
confidence bands method comes from its simplicity, as it is probably the method most 
researchers would naturally use to estimate 𝐷∗ from the duration-response curve. However, it 
has several limitations, the most important being that the pointwise confidence bands for the 
curve are not the same as the confidence interval for the difference between two specific 
points on the curve. 
 
While the delta method (2.2) addresses this problem, it is affected by at least one other issue, 
at least when using fractional polynomials5 as the flexible regression method: specifically, 
that model selection variability should be taken into account6. The two bootstrap methods in 
Sections 2.3 and 2.4 are theoretically appealing strategies to solve this problem, as repeating 
the fractional polynomial selection step for each bootstrap sample is one approach to address 
model selection variability.  
 
However, with the delta method (2.2) and the bootstrap CI method (2.3) we estimate multiple 
confidence intervals around the curve, and compare each upper bound against the maximum 
tolerable risk difference. Hence, we may theoretically run into a multiplicity issue. However, 
our repeated tests are performed with the goal to solve an equation, rather than to formally 
compare different duration arms, making this less problematic.  
 
8 
 
When the model used to estimate the duration-response curve is correct, we expect the 
bootstrap duration CI method (2.4) to estimate a confidence interval for 𝐷∗ that covers the 
true value at the nominal level. The assumption about model correctness is important; our 
choice of fractional polynomials as the preferred analysis method was originally driven by 
the fact that in many situations we are not confident what the true underlying model is, and 
hence flexible models are preferred. While the standard fractional polynomial algorithm was 
built as a parsimonious modelling technique7, in our application, with a single covariate and a 
reasonable number of expected events, a modified algorithm selecting exactly two 
polynomial terms rather than a maximum of two is likely to be preferable, and makes it easier 
to satisfy the assumption that the model used is approximately correct. Henceforth, we refer 
to this method as the modified fractional polynomial analysis. 
  
3. Simulations 
We compared the methods presented above in a simulation study designed using the recently 
proposed ADEMP framework8. 
 
3.1. Aims  
The main aim is to compare different strategies of drawing inference from the duration-
response curve. Specific questions are: are bootstrap methods necessary, or does the simpler 
delta-method suffice? Is the modified fractional polynomial analysis preferable? How 
problematic is the multiplicity issue with the bootstrap CI method? 
  
3.2. Data-generating mechanisms 
 
9 
 
The DURATIONS design aims to be resilient to the true underlying duration-response 
relationship. Consequently, we generate data under sixteen different scenarios that are listed 
and plotted in the additional material online, including the eight scenarios in (Quartagno et al, 
2018). These reflect a wide range of possible duration-response relationships, including both 
those generated by fractional polynomials and those generated from sigmoid functions 
(which are not strictly within the fractional polynomial paradigm). For comparisons, we re-
scale the x-axis so that the minimum duration considered (𝐷ெூே) is 8 days, and the maximum 
𝐷ெ஺௑ is 20 days, with 7 randomised arms evenly spread between them (8, 10, 12, 14, 16, 18, 
20). We generate 1000 data sets from each scenario of N=500 individuals. Using the same 
process, we additionally generate 200 datasets of N=750 and N=1000 individuals, to explore 
the sensitivity of results to total sample size. 
 
3.3. Estimation targets 
 
We assume the estimation target of interest is the duration 𝐷∗ leading to a cure rate that is 𝛿% 
less than at the longest (and currently used) duration 𝐷ெ஺௑. This approximately corresponds 
to the shortest duration non-inferior to standard-of-care within a non-inferiority margin 𝛿 on 
the risk difference scale. In our base case, we consider 𝛿 = 10%, a margin that has been 
recommended for example by FDA for non-inferiority trials of antibiotics for adult bacterial 
community acquired pneumonia9. However, as in some applications this may be considered 
too large a margin, we additionally explore the sensitivity of results using 𝛿 = 5%. This risk 
difference based estimation target might not be optimal in all applications, and hence in 
Section 4 we propose different estimation targets. 
 
3.4. Methods 
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We compare the four different methods of estimating 𝐷∗෢  described above. For the bootstrap 
methods, we use M=500 replications. For method 2.3, we build confidence intervals using the 
BCa method10, which is based on the percentiles of the bootstrap distribution, but with 
adjustments to account for both bias and skewness. For method 2.4, we use the percentile 
confidence interval instead, as BCa is not applicable in some scenarios where the bootstrap 
distribution is truncated at 8 days. Additionally, we compare the standard (i.e. selecting up to 
two polynomial terms) and modified (i.e. selecting exactly two terms) fractional polynomial 
algorithms for method 2.4.  
 
3.5. Performance measures 
 
The choice of performance measures is not straightforward. Unlike most randomised trial 
designs, our DURATIONS randomised design does not define a null hypothesis to test. This 
is because the longest treatment duration we randomise patients to is already known to be 
(usually highly) effective, and our aim is only to find the most appropriate shorter duration. 
Under very simple assumptions, i.e. that the duration-response curve is continuous and 
monotonic, we know that either there is a duration 𝐷∗ in the interval [𝐷ெூே;  𝐷ெ஺௑] such that 
𝜋஽∗ = 𝜋஽ಾಲ೉ − 𝛿, or that even the shortest duration is sufficiently effective, i.e. 𝜋஽∗ =
𝜋஽ಾ಺ಿ ≥ 𝜋஽ಾಲ೉ − 𝛿. 
 
Given this, and having defined our estimation target, we define three main performance 
measures of interest: 
1) Type-1 Error: in this context we define type-1 error as the probability that our trial 
ends up recommending a duration 𝐷∗෢  that is insufficiently effective: 
𝑇𝑦𝑝𝑒 1 𝐸𝑟𝑟𝑜𝑟 = 𝑃(𝜋஽∗෢ < 𝜋஽ಾಲ೉ − 𝛿) 
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2) Full Power: there are several ways to define power compared to standard hypothesis 
testing. We define full power as the probability that the trial ends up recommending 
the actual optimal duration, that is the minimum effective (integer) duration: 
𝐹𝑢𝑙𝑙 𝑃𝑜𝑤𝑒𝑟 = 𝑃(𝐷∗෢ = min
஽೔
( 𝜋஽೔ ≥ 𝜋஽ಾಲ೉ − 𝛿)) 
3) Partial Power: designing a trial to reach high levels of Full Power might be difficult, 
but one might be interested in simply finding an effective duration that is shorter than 
the recommended one, even if it is not necessarily the minimum effective duration. 
We define the partial power as the probability that our trial identifies one such 
duration: 
𝑃artial 𝑃𝑜𝑤𝑒𝑟 = 𝑃(𝜋஽∗෢ ≥ 𝜋஽ಾಲ೉ − 𝛿) 
Additionally, we measure performance by considering the distribution of all the 
recommended durations 𝐷∗෢ . 
 
3.6. Results 
 
Figure 2 compares type-1 error and partial power across the different methods. It is 
immediately clear that type-1 error is not adequately controlled under certain scenarios. 
These scenarios are mainly those where the curvature at the optimal duration is positive, i.e. 
those for which steepness of the curve is increasing at the optimal duration. These are 
arguably not the most likely scenarios in our settings, as we expect to be investigating part of 
the duration-response curve where the curve is asymptoting; nevertheless, it is preferable to 
use methods like those in Section 2.3 and 2.4 that provide better inference by taking into 
account model selection variability. Differences between the two bootstrap methods are less 
marked (Table 2), although type-1 error is generally slightly lower using the bootstrap 
duration CI method (2.4). 
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In terms of analysis model, the modified fractional polynomial method is preferable with 
regards to type-1 error (Figure 2 and Table E in the additional material). There are only a few 
scenarios under which Methods 2.3 and 2.4 fail to control the type-1 error within 2.5%, 
namely scenarios 7, 8, 13 and 14 (Figure 3). However, this figure shows that the difference 
between the estimated minimum duration and the actual minimum acceptable duration is 
small (<=1 day) in these scenarios and that the 2.5th percentiles of recommended durations 
(and associated cure rate) are actually very close to the optimal duration (and corresponding 
cure rate). 
 
In terms of power, differences are not as pronounced, and all methods achieve very good 
partial power (>90%) under most scenarios. Of note, the simulated sample size (N=500) was 
determined to estimate the duration-response curve within a certain average absolute error 
(5%), and not to achieve a specific power under any of our scenarios. As expected, full power 
is always substantially lower, particularly in scenarios where the cure rate at the optimal 
duration is very close to the minimum acceptable cure rate. Again, differences between 
different methods are not substantial. 
  
The only scenario where full power exceeds 80% is Scenario 4 (Table 2, Tables A-D in 
additional material), i.e. constant cure rate at every duration. In this scenario, full power can 
be broadly interpreted as the power of a non-inferiority trial of 𝐷ெ஺௑ against 𝐷ெூே with a 𝛿 % 
non-inferiority margin, where the two durations have exactly the same true cure rate. 
 
Finally, conclusions are similar using 𝛿 = 5% (Figure a in additional material), although 
power is lower in all scenarios. In particular, partial power remains quite low for Scenario 14, 
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only crossing the 80% threshold for N=1000. Full power remains very low for all scenarios 
and sample sizes. 
 
 
4. Alternative objectives 
 
In this simulation study, we assumed that the trial objective was to find the minimum 
duration 𝐷∗ such that 𝜋஽∗ ≥ 𝜋஽ಾಲ೉ − 𝛿. This clearly corresponds with standard non-
inferiority trials designed with margin 𝛿ேூ on the risk difference scale: in both, we assume 
that if the cure rate in the intervention arm is poorer only within a certain limit, then its 
secondary advantages make it preferable to the control arm. In this section we discuss 
different objectives. Some are again in common with standard non-inferiority trials, while 
others are specific to our design.  
 
4.1. Fixed rate  
Instead of considering a fixed difference in cure rate compared to control, one might simply 
want to identify the duration 𝐷∗ leading to a specific cure rate 𝜋∗: 
𝐷∗ = min
஽೔
( 𝜋஽೔ ≥ 𝜋
∗) 
This may be reasonable when there is good prior information on the expected cure rate 𝜋஽ಾಲ೉ 
at the control duration 𝐷ெ஺௑, although one can never be sure that the population recruited 
will reflect historical controls. Methods 2.3 and 2.4 could be used as analysis methods for this 
estimation target.  
 
4.2. Fixed risk ratio 
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Analogously to a standard non-inferiority trial, the margin 𝛿 could also be defined on a 
relative scale; for example, as the proportion of the cure rate at 𝐷ெ஺௑ that should be 
preserved in order to consider the shorter duration preferable: 
min
஽೔
( 𝜋஽೔ ≥ 𝛿 ∗ 𝜋஽ಾಲ೉) 
For example, if we wanted to preserve 90% of the effect of treatment at 𝐷ெ஺௑, we would 
choose 𝛿 = 0.9. 
 
4.3. The acceptability frontier 
 
While non-inferiority trials naturally have a single non-inferiority margin 𝛿ேூ, in 
DURATIONS trials it might instead be logical to have different margins for each specific 
duration 𝐷௜. For example, for a duration that is a half of 𝐷ெ஺௑, we might be happy to tolerate 
a slightly larger 𝛿 than for a duration equal to two thirds of 𝐷ெ஺௑, assuming that advantages 
of shorter durations generally increase as the duration reduces. Hence, the objective of the 
trial might be to find the duration 𝐷∗ such that: 
𝐷∗ = min
஽೔
( 𝜋஽೔ ≥ 𝜋஽ಾಲ೉ − 𝛿(𝐷௜)) 
where 𝛿(𝐷௜) is the function that indicates the acceptable loss in cure rate for each duration 𝐷௜. 
We call this the Acceptability Frontier, a possible example of which is the grey line in Figure 
1. 
  
4.4. Maximum gradient 
Instead of targeting a specific cure rate, or difference in cure rate, investigators might be 
interested in the gradient of the duration-response curve. If we expect the curve to asymptote 
after a certain duration D*, then we might define such D* as the point after which the 
gradient of the function is always below a certain threshold 𝛿: 
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𝐷∗ = min
஽೔
( ∇𝜋(𝐷) ≤ 𝛿, ∀𝐷 > 𝐷௜) 
For example, in the scenarios above, we found that 𝛿 = 2% was a reasonable value for this 
threshold. 
 
4.5. Additional simulations  
We performed additional simulations to explore operating characteristics of the bootstrap 
duration CI method (2.4) with each of these different estimation targets. We analysed the 
same 1000 datasets generated for the 16 scenarios in our base case simulations, with N=500. 
As the target cure rate, we chose in each scenario the value 10% less than the true cure rate at 
the longest duration. For the fixed risk ratio, we used 𝛿 = 0.9. The acceptability frontier was a 
linear function, such that the largest acceptable risk difference at 𝐷ெூே was 10%, and at 18 
days 5% (Figure 1). Finally, the maximum acceptable gradient was taken to be 2%. For this 
last estimation target we did not use method 2.4, but we simply looked at the single point 
estimate in the data. Results ( Tables D-G in the additional material) show reasonable 
performance for the first three alternative estimation targets. For the maximum gradient 
target, type-1 errors are large, and further analysis refinements would be necessary to use 
this. 
 
5. Analysis example 
 
Given the simulation results, here we sketch our favoured three-step approach to analysing a 
DURATIONS trial. First, an acceptability frontier should be defined, answering the question 
“what would the non-inferiority margin be for a trial comparing the longest duration to each 
shorter one?”. In this example, we assume a reasonable non-inferiority margin is 10% cure 
rate difference compared to the control duration, as in the base-case scenario of our 
simulations (Figure 4). Second, we run our modified fractional polynomial algorithm to 
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estimate the duration-response curve (black solid line in Figure 4). Third, we use the 
bootstrap (BCa method10) to find the confidence interval either around our estimated optimal 
duration 𝐷∗෢  or the differences in cure rate from the control at each duration (left and right 
panel of Figure 4 respectively). In this example, both methods recommend 𝐷∗෢ = 13 days as 
optimal duration.  
 
6. Discussion 
In this article we have compared different strategies for drawing inference from a duration-
response curve estimated using a DURATIONS randomised trial design. We defined 
quantities analogous to type-1 error and power in this scenario, and found a method based on 
bootstrap re-sampling — to estimate the duration associated with a specific cure rate 
difference from control — has good inferential properties when combined with a modified 
fractional polynomial analysis method. This is therefore our recommended approach.  
 
One issue with the standard non-inferiority design for identifying optimal treatment duration 
is the potential for so-called ‘bio-creep’, i.e. the erosion of efficacy from sequentially testing 
for non-inferiority shorter durations, iteratively updating the control duration to one 
previously shown to be non-inferior11. One advantage of the DURATIONS design is that it 
avoids this problem, as all the durations are evaluated in the same trial. Another advantage is 
its resilience; in a standard non-inferiority trial, whenever a single design parameter turns out 
to have been badly misjudged, the whole trial can quickly lose power or interpretability. By 
contrast, the DURATIONS design has been developed to be flexible enough to maintain good 
properties against a wide range of duration-response curves. 
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6.1. Extensions 
Design and analysis of randomised trials often intersect, and hence what is an analysis 
decision (how to analyse and draw inference from the observed data) also has design 
implications (how to best design a trial that we aim to analyse in a particular way). Hence, 
future work will investigate how to design a DURATIONS randomised trial that we aim to 
analyse with methods presented here. 
 
We focused on binary outcomes, but similar methods could be easily used for continuous and 
survival outcomes, with the only additional complication of having to derive a suitable 
estimation target. When developing the target based on the acceptability frontier, we assumed 
that this frontier was subjectively drawn by the analyst, based on assumptions about the 
trade-offs between shortening duration and loss of treatment efficacy. An alternative could be 
to derive the acceptability frontier using available data on the secondary advantages of 
shorter durations. For example, if the goal was to design a DURATIONS trial in Hepatitis C, 
the acceptability frontier could be built using data on costs. 
 
Future work could include investigating the effect of including additional covariates in the 
fractional polynomial model, for example age or sex, if there was evidence that the optimal 
duration might vary depending on these factors. It could also investigate using an adaptive 
design, to allow for closure of poorly performing arms (i.e. those at the lowest durations)4.  
 
For TB and related settings, where the optimal duration might be investigated for a new drug 
or new regimen, it is important to investigate the best way to include a formal comparison 
with an independent control treatment of fixed duration, for example with the standard 6-
month TB treatment course with rifampicin, isoniazid, pyrazinamide and ethambutol.  
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6.2. Conclusions 
We recently proposed a DURATIONS randomised trial design as an alternative to a standard 
two-arm non-inferiority design when the goal is to optimise treatment duration. Here we have 
investigated the operating characteristics of various methods of drawing inference from the 
duration-response curve and found that a method based on bootstrap to estimate a duration 
associated with a specific cure rate has good properties and is an appealing choice. Using this 
analysis method, DURATIONS randomised trials could help identify better treatment 
durations in an optimal way across many illnesses4.  
 
Code 
The code used for the simulations will be made available on the GitHub page of the first 
author. 
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Figure 1: Example of estimated duration-response curve (solid, black), drawn against three possible 
acceptability frontiers (dotted, red = 10% fixed risk difference; dashed, blue = 5% fixed risk difference; 
solid, grey= duration-specific frontier, as in section 4.3). 
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Table 1: Properties of different methods to estimate confidence intervals.  
Method Targets 
difference in 
efficacy 
between two 
points 
Addresses 
model selection 
uncertainty 
Addresses 
multiplicity 
issue 
Analysis 
method used in 
simulations 
Confidence 
Bands (§2.1) 
No No No Modified 
fractional 
polynomials 
(gamlss package 
in R) 
Delta Method 
(§2.2) 
Yes No No Modified 
fractional 
polynomials 
(gamlss) 
Bootstrap CI 
(§2.3) 
Yes Yes No Modified 
fractional 
polynomials 
(gamlss) 
Bootstrap 
Duration CI 
(§2.4) 
Yes Yes Yes Both standard 
(mfp package) 
and modified 
(gamlss) 
fractional 
polynomials 
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Figure 2: Type-1 Error and Partial Power (probability of recommending any sufficiently effective shorter 
duration) of the 5 analysis methods across the 16 simulation scenarios. Bootstrap MFP uses the 
Bootstrap duration CI method, but using the standard fractional polynomial approach as the analysis 
method (as in R package mfp).  
 
23 
 
 
Figure 3: Duration recommended and associated cure rate across the 16 simulation scenarios using 
method 2.4, with base-case design parameters (estimation target=shortest duration non-inferior to 20 
days within 10% risk difference). The vertical bar indicates the true minimum effective duration. 
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Table 2: Results from using methods 2.3 and 2.4, with the modified fractional polynomial analysis method and base-case 
design parameters (estimation target=shortest duration non-inferior to 20 days within 10% risk difference). In italics: 
scenarios for which the upper bound of the Monte-Carlo confidence interval for type-1 error was not strictly controlled 
within 2.5%, with Monte-Carlo confidence interval. See additional material Tables A-B for other methods. 
 Partial 
Power 
(%) 
Full Power 
(%) 
Type-1 Error 
(%) 
(Target 
value: 2.5%) 
True 
Min 
Duration 
Estimated 
Minimum 
Duration 
Recomm. 
Estimated 
2.5th Perc 
Duration 
Recomm. 
Estimated 
Median 
Duration 
Recomm. 
Method 2.3 
(Bootstrap 
CI): 
       
Scenario 1 98.2 9.8 1.8 13.1 12 14 16 
Scenario 2 99.2 16.5 0.8 14.5 14 15 16 
Scenario 3 94.5 10 1.6 15.9 15 16 18 
Scenario 4 100 82.7 0 8.0 8 8 8 
Scenario 5 99.6 5.4 0.4 9.7 9 10 12 
Scenario 6 99.7 3.2 0.3 10.8 10 11 14 
Scenario 7 94.4 30.7 4.3 (3.0,5.6) 16.2 14 16 18 
Scenario 8 87 12.9 10.1(8.2,12) 15.0 8 15 17 
Scenario 9 100 2.6 0 12.6 13 13 14 
Scenario 10 99.9 0.8 0 15.2 16 17 18 
Scenario 11 79 8.6 0.1 16.8 16 17 18 
Scenario 12 98.9 29.9 1.1 11.2 11 12 13 
Scenario 13 95.5 26.6 4.5 (3.2,5.8) 8.1 8 8 10 
Scenario 14 56.2 8.6 3.8 (2.6,5.0) 15.0 8 15 17 
Scenario 15 99.3 4.8 0.7 12.5 12 13 15 
Scenario 16 99.8 4.9 0.2 12.0 11 12 14 
Method 2.4 
(Bootstrap 
Duration CI): 
       
Scenario 1 97.7 9.9 2.3 13.1 11 14 16 
Scenario 2 99.7 14.4 0.3 14.5 14 15 16 
Scenario 3 99 5.3 1 15.9 14 16 18 
Scenario 4 100 86.1 0 8.0 8 8 8 
Scenario 5 99.9 5.4 0.1 9.7 9 10 12 
Scenario 6 99.7 3.5 0.3 10.8 10 11 14 
Scenario 7 95.2 46.8 4.8 (3.5,6.1) 16.2 15 16 17 
Scenario 8 93.3 15.7 6.7 (5.2,8.2) 15.0 8 15 17 
Scenario 9 100 2.3 0 12.6 13 14 14 
Scenario 10 100 0.6 0 15.2 16 17 17 
Scenario 11 99.9 9.8 0.1 16.8 16 17 18 
Scenario 12 99 40.3 1 11.2 11 12 13 
Scenario 13 96.3 29 3.7 (2.5,4.9) 8.1 8 8 10 
Scenario 14 95.5 5.7 4.5 (3.2,5.8) 15.0 8 15 18 
Scenario 15 99.3 5 0.7 12.5 12 13 15 
Scenario 16 99.8 4.6 0.2 12.0 11 12 14 
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Figure 4: Analysis example for a hypothetical trial. On the left panel, the duration-response curve is 
estimated and then a bootstrap CI is built around the point where it crosses the acceptability frontier. On 
the right panel, bootstrap CIs are built around the difference in efficacy (cure rate) between each arm and 
the longest (d=20). 
Table A: Results from using method 2.1, Model Confidence Bands, with base-case design parameters (estimand=shortest 
duration non-inferior to 20 days within 10% risk difference)  
In italics: scenarios for which type 1 error was not strictly controlled within 2.5%. Note the standard fractional 
polynomial algorithm was used here, as mfp is the only R package returning standard errors for the data.  
 Partial 
Power (%) 
Full Power 
(%) 
Type 1 
Error (%) 
True Min 
Duration 
Estimated 
Minimum 
Duration 
Estimated 
2.5th Perc 
Duration 
Estimated 
Median 
Duration 
Scenario 1 89.7 11.7 10.3 13.1 10 12 16 
Scenario 2 99.2 15.2 0.8 14.5 13 15 16 
Scenario 3 97.4 10 2.5 15.9 12 16 18 
Scenario 4 100 79.8 0 8.0 8 8 8 
Scenario 5 99.7 9.3 0.3 9.7 9 10 12 
Scenario 6 97.6 8.4 2.4 10.8 9 11 13 
Scenario 7 93.3 23.2 6.7 16.2 14 16 18 
Scenario 8 85.4 21.3 14.4 15.0 8 13 17 
Scenario 9 100 4.8 0 12.6 13 13 14 
Scenario 10 100 2.5 0 15.2 16 17 18 
Scenario 11 94.2 13.9 2.2 16.8 16 17 18 
Scenario 12 97 53.5 3 11.2 11 11 12 
Scenario 13 94.8 46.7 5.2 8.1 8 8 9 
Scenario 14 69 14.1 13.9 15.0 8 11 17 
Scenario 15 92.2 11.7 7.8 12.5 11 12 15 
Scenario 16 99.1 14.7 0.9 12.0 11 12 14 
 
Table B: Results from using method 2.2, Delta method CI, with base-case design parameters (estimand=shortest 
duration non-inferior to 20 days within 10% risk difference). Partial and full power, Type-1 Error, Real minimum 
duration, minimum, 2.5% percentile and median duration recommended. In italics: scenarios for which type 1 error was 
not strictly controlled within 2.5%. 
 Partial 
Power (%) 
Full Power 
(%) 
Type 1 
Error (%) 
True Min 
Duration 
Estimated 
Minimum 
Duration 
Estimated 
2.5th Perc 
Duration 
Estimated 
Median 
Duration 
Scenario 1 96.6 13.1 3.4 13.1 11 13 15 
Scenario 2 96.8 29.5 3.2 14.5 14 14 16 
Scenario 3 95.1 18.9 3.5 15.9 13 15 17 
Scenario 4 100 88.9 0 8.0 8 8 8 
Scenario 5 99.8 7.6 0.2 9.7 9 10 12 
Scenario 6 99.5 4.8 0.5 10.8 10 11 14 
Scenario 7 85.2 46 14.8 16.2 14 16 17 
Scenario 8 82.7 24.1 17 15.0 8 14 17 
Scenario 9 100 1.7 0 12.6 13 14 14 
Scenario 10 100 0.9 0 15.2 16 17 17 
Scenario 11 86.6 8.2 0.1 16.8 16 17 18 
Scenario 12 99 33.5 1 11.2 11 12 13 
Scenario 13 94.9 26.1 5.1 8.1 8 8 10 
Scenario 14 64.1 16.2 6.7 15.0 8 14 17 
Scenario 15 98.5 6.1 1.5 12.5 12 13 15 
Scenario 16 99.8 3.9 0.2 12.0 11 12 14 
 
  
Table C: Results from using method 2.4, Bootstrap duration CI, but using standard fractional polynomials (mfp package 
in R) , with base-case design parameters (estimand=shortest duration non-inferior to 20 days within 10% risk 
difference). Partial and full power, Type-1 Error, Real minimum duration, minimum, 2.5% percentile and median 
duration recommended. In italics: scenarios for which type 1 error was not strictly controlled within 2.5%. 
 Partial 
Power (%) 
Full Power 
(%) 
Type 1 
Error (%) 
True Min 
Duration 
Estimated 
Minimum 
Duration 
Estimated 
2.5th Perc 
Duration 
Estimated 
Median 
Duration 
Scenario 1 98.7 32.4 1.3 13.1 12 14 15 
Scenario 2 95.6 44 4.4 14.5 14 14 16 
Scenario 3 89.8 25.1 10.2 15.9 13 15 17 
Scenario 4 100 86.3 0 8.0 8 8 8 
Scenario 5 100 0.4 0 9.7 10 11 12 
Scenario 6 100 0.1 0 10.8 11 13 14 
Scenario 7 81.6 41.5 18.4 16.2 14 15 17 
Scenario 8 57.6 13.1 42.4 15.0 8 12 16 
Scenario 9 100 1.6 0 12.6 13 14 15 
Scenario 10 100 0.2 0 15.2 16 17 17 
Scenario 11 100 0.2 0 16.8 17 18 18 
Scenario 12 99.4 23.8 0.6 11.2 11 12 14 
Scenario 13 95.4 9.3 4.6 8.1 8 8 11 
Scenario 14 60.4 16.6 39.6 15.0 8 12 16 
Scenario 15 99.8 4.3 0.2 12.5 12 13 14 
Scenario 16 100 0.5 0 12.0 12 13 15 
 
Table D: Results from using method 2.4, Bootstrap duration CI, targeting a fixed cure rate estimand. Partial and full 
power, Type-1 Error, Real minimum duration, minimum, 2.5% percentile and median duration recommended. In italics: 
scenarios for which type 1 error was not strictly controlled within 2.5%. 
 Partial 
Power (%) 
Full Power 
(%) 
Type 1 
Error (%) 
True Min 
Duration 
Estimated 
Minimum 
Duration 
Estimated 
2.5th Perc 
Duration 
Estimated 
Median 
Duration 
Scenario 1 96.3 13.7 3.2 13.1 12 13 16 
Scenario 2 99.4 13.1 0.5 14.5 14 15 16 
Scenario 3 94.7 5.7 0.4 15.9 15 16 18 
Scenario 4 100 87 0 8.0 8 8 8 
Scenario 5 99.9 4.3 0.1 9.7 9 10 12 
Scenario 6 99.9 2.4 0.1 10.8 10 12 13 
Scenario 7 93.9 36.3 3.3 16.2 15 16 18 
Scenario 8 88.2 23.3 9.3 15.0 8 14 17 
Scenario 9 100 1.1 0 12.6 13 14 14 
Scenario 10 100 6.1 0 15.2 16 16 17 
Scenario 11 78.9 9.4 0.2 16.8 16 17 18 
Scenario 12 99.9 48.3 0.1 11.2 11 12 13 
Scenario 13 97.2 43.8 2.8 8.1 8 8 10 
Scenario 14 76.7 11.6 7.4 15.0 8 14 18 
Scenario 15 98.5 10.7 1.4 12.5 11 13 15 
Scenario 16 100 5.8 0 12.0 12 12 13 
 
 
Table E: Results from using method 2.4, Bootstrap duration CI, targeting a fixed risk ratio estimand. Partial and full 
power, Type-1 Error, Real minimum duration, minimum, 2.5% percentile and median duration recommended. In italics: 
scenarios for which type 1 error was not strictly controlled within 2.5%. 
 Partial 
Power (%) 
Full Power 
(%) 
Type 1 
Error (%) 
True Min 
Duration 
Estimated 
Minimum 
Duration 
Estimated 
2.5th Perc 
Duration 
Estimated 
Median 
Duration 
Scenario 1 98 6.8 2 13.3 11 14 16 
Scenario 2 99.8 13.5 0.2 14.7 14 15 16 
Scenario 3 99.3 3.7 0.7 16.0 14 16 18 
Scenario 4 100 84.1 0 8.0 8 8 8 
Scenario 5 99.9 4.8 0.1 9.7 9 10 12 
Scenario 6 97 8.9 3 11.0 10 11 14 
Scenario 7 96 42.2 4 16.4 15 16 18 
Scenario 8 95.2 14.2 4.8 15.3 8 15 17 
Scenario 9 100 1.6 0 12.6 13 14 14 
Scenario 10 100 0.5 0 15.2 16 17 17 
Scenario 11 95.5 64 4.5 17.1 17 17 18 
Scenario 12 99.6 32 0.4 11.3 11 12 13 
Scenario 13 97.7 22.9 2.3 8.2 8 9 11 
Scenario 14 97.4 3.2 2.6 16.0 9 15 18 
Scenario 15 99.6 4.2 0.4 12.6 12 13 15 
Scenario 16 96.4 19.8 3.6 12.1 11 12 14 
 
Table F: Results from using method 2.4, Bootstrap duration CI, targeting an acceptability frontier estimand. Partial and 
full power, Type-1 Error, Real minimum duration, minimum, 2.5% percentile and median duration recommended. In 
italics: scenarios for which type 1 error was not strictly controlled within 2.5%. 
 Partial 
Power (%) 
Full Power 
(%) 
Type 1 
Error (%) 
True Min 
Duration 
Estimated 
Minimum 
Duration 
Estimated 
2.5th Perc 
Duration 
Estimated 
Median 
Duration 
Scenario 1 98.7 3 1.3 14.8 12 15 18 
Scenario 2 99.8 6.3 0.2 16.0 15 16 18 
Scenario 3 96.3 14.9 1.8 17.6 16 18 19 
Scenario 4 100 86.1 0 8.0 8 8 8 
Scenario 5 99.9 2.9 0.1 9.9 9 10 13 
Scenario 6 98 3.6 2 11.6 10 12 15 
Scenario 7 99.3 27.9 0.7 17.8 17 18 19 
Scenario 8 92.2 28.4 7.5 17.3 8 17 19 
Scenario 9 100 0.2 0 12.7 13 14 15 
Scenario 10 100 0 0 15.4 17 17 18 
Scenario 11 86.9 6.2 0.3 17.8 17 18 19 
Scenario 12 99.7 20.8 0.3 11.4 11 12 13 
Scenario 13 96.3 24.9 3.7 8.1 8 8 11 
Scenario 14 47.1 5.2 4.4 17.8 8 17 19 
Scenario 15 99.3 2.7 0.7 13.6 12 14 17 
Scenario 16 98.4 9.6 1.6 12.5 11 13 15 
 
 
 
Table G: Results from using method 2.4, Bootstrap duration CI, targeting a maximum gradient estimand. Partial and full 
power, Type-1 Error, Real minimum duration, minimum, 2.5% percentile and median duration recommended. In italics: 
scenarios for which type 1 error was not strictly controlled within 2.5%. Power is not available for scenario 14, for which 
the gradient is too steep even at the longest duration.  
 Partial 
Power (%) 
Full Power 
(%) 
Type 1 
Error (%) 
True Min 
Duration 
Estimated 
Minimum 
Duration 
Estimated 
2.5th Perc 
Duration 
Estimated 
Median 
Duration 
Scenario 1 67 15.3 29.8 13.939 8 20 15 
Scenario 2 62.5 30.3 36.9 16.848 12 20 17 
Scenario 3 0 42.7 57.3 19.152 8 20 19 
Scenario 4 93.2 70.6 0 8 8 20 8 
Scenario 5 77.3 55 19 11.152 10 20 12 
Scenario 6 90.1 32.3 4.7 11.636 8 20 13 
Scenario 7 0 42.6 57.4 19.273 8 20 19 
Scenario 8 12 42.8 57.2 18.788 8 20 17 
Scenario 9 23 0.1 0 13.818 14 20 20 
Scenario 10 86.6 0 0 16.242 18 20 19 
Scenario 11 0 63.1 36.9 19.152 18 20 20 
Scenario 12 85 25.5 0.1 12.848 12 20 14 
Scenario 13 73.3 32 14 9.333 8 20 11 
Scenario 14 NA NA 52.7 20 8 20 18.5 
Scenario 15 46 23.9 50.3 14.303 8 20 14 
Scenario 16 46 36.7 27.1 14.061 13 20 15 
 
  
Figure A: Partial and Full Power using bootstrap duration CI (2.4) with 6 different designs. The worst scenario in terms of partial power for each design and the best in terms of full power 
are indexed. 
 
Table H: Simulation Scenarios. 
Type / Equation Plot Type / Equation Plot 
1) Linear Duration-
Response curve on log-
odds scale: 
 
𝜋 =
𝑒଴.଼ହା଴.ଵ଻(஽ି଼)
1 + 𝑒଴.଼ହା଴.ଵ଻(஽ି଼)
 
 
9)    Logistic Growth Model 
– Early Growth: 
𝜋 = 0.05 +
0.9
1 + 𝑒ଶଷିଶ஽
 
 
2) Quadratic + linear 
relation on log-odds 
scale:  
 
𝜋 =
𝑒଴.଺ଶା଴.ଵଷ(஽ି଼)ା଴.଴ଵ(஽ି଼)మ
1 + 𝑒଴.଺ଶା଴.ଵଷ(஽ି଼)ା଴.଴ଵ(஽ି଼)మ
 
 
10)    Logistic Growth 
Model – Later Growth: 
𝜋 = 0.05 +
0.9
1 + 𝑒ଶ଼ିଶ஽
 
 
3) Quadratic relation on 
log-odds scale: 
 
𝜋 =
𝑒଴.଼ହା଴.଴ଵ(஽ି଼)మ
1 + 𝑒଴.଼ହା଴.଴ଵ(஽ି଼)మ
 
 
11)    Gompertz Curve A: 
 
𝜋 = 0.9𝑒ି௘షబ.ఱ(ವషభయ) 
 
4) Constant response: 
 
 
𝜋 = 0.95 
 
12)    Gompertz Curve B: 
 
𝜋 = 0.9𝑒ି௘ష(ವషవ)  
 
5) Logarithmic relation on 
log-odds scale: 
 
𝜋 =
𝑒଴.଼ହାଵ.ଵଽ௟௢௚(஽ି଼)
1 + 𝑒଴.଼ହାଵ.ଵଽ௟௢௚(஽ି଼)
 
 
13)    Gompertz Curve C: 
 
𝜋 = 0.9𝑒ି௘షమ(ವషళ) 
 
6) Square rooted relation 
on log-odds scale: 
 
𝜋 =
𝑒଴.଺ଶା଴.଺଻√஽ି଼
1 + 𝑒଴.଺ଶା଴.଺଻√஽ି଼)
 
 
14)    Quadratic on 
probability scale: 
𝜋 = 0.7 + 0.01(𝐷 − 8)ଶ 
 
7) Cubic relation on log-
odds scale: 
 
 
𝜋 =
𝑒ଵ.ଵ଴ା଴.଴଴ଶ(஽ି଼)య
1 + 𝑒ଵ.ଵ଴ା଴.଴଴ଶ(஽ି଼)య
 
 
15)    Quadratic on 
probability scale: 
𝜋
= 0.7 − 0.01(𝐷 − 8)ଶ
+ 0.04(𝐷 − 8) 
 
8) Cubic + Quadratic 
relation on log-odds 
scale: 
 
𝜋
=
𝑒ଵ.ଷଽା଴.଴଴ଶ(஽ି଼)మା଴.଴଴ଵ(஽ି଼)య
1 + 𝑒ଵ.ଷଽା଴.଴଴ଶ(஽ି଼)మା଴.଴଴ଵ(஽ି଼)య
 
 
16)    Linear Spline: 
D<11: 
 𝜋 = 0.5 + 0.10(𝐷 − 8) 
D>11&D<14:  
 𝜋 = 0.8 + 0.04(𝐷 − 11) 
D>14: 
  𝜋 = 0.94 + 0.01(𝐷 − 14) 
 
 Appendix A. Delta Method Confidence Interval.  
Suppose we ran our fractional polynomial algorithm estimating our duration-response curve: 
𝜋(𝐷) = 𝑙𝑜𝑔𝑖𝑡ିଵ(𝛼ො + 𝛽መ𝐷 + 𝛾ො𝐷ଶ), 
where a linear and a quadratic term have been selected by the algorithm, and ൫𝛼ො, 𝛽መ, 𝛾ො൯ is the vector 
of estimated model parameters. Our goal is to obtain a confidence interval for the difference in 
efficacy between two specific durations 𝐷ଵ and 𝐷ଶ . This can be written as a function of model 
parameters, as: 
 𝑓(𝛼, 𝛽, 𝛾) = 𝜋(𝐷ଵ) − 𝜋(𝐷ଶ) = 𝑙𝑜𝑔𝑖𝑡ିଵ(𝛼 + 𝛽𝐷ଵ + 𝛾𝐷ଵଶ) − 𝑙𝑜𝑔𝑖𝑡ିଵ(𝛼 + 𝛽𝐷ଶ + 𝛾𝐷ଶଶ). 
Let 𝛀 be the variance covariance matrix of the three regression parameters, so that approximately: 
൭
𝛼
𝛽
𝛾
൱ ~𝑁 ቌ൭
𝛼ො
𝛽መ
𝛾ො
൱ , 𝛀ቍ 
And let the Jacobian of function 𝑓(𝛼, 𝛽, 𝛾) be the vector of partial derivatives with respect to the 
three variables: 
𝑱𝒇(𝛼, 𝛽, 𝛾) = ൬
𝜕
𝜕𝛼
𝑓,
𝜕
𝜕𝛽
𝑓,
𝜕
𝜕𝛾
𝑓൰ =  ൭
𝑒ఈାఉ஽భାఊ஽భమ
(𝑒ఈାఉ஽భାఊ஽భమ)ଶ
−
𝑒ఈାఉ஽మାఊ஽మమ
(𝑒ఈାఉ஽మାఊ஽మమ)ଶ
 
, 𝐷ଵ
𝑒ఈାఉ஽భାఊ஽భమ
(𝑒ఈାఉ஽భାఊ஽భమ)ଶ
− 𝐷ଶ
𝑒ఈାఉ஽మାఊ஽మమ
(𝑒ఈାఉ஽మାఊ஽మమ)ଶ
, 𝐷ଵଶ
𝑒ఈାఉ஽భାఊ஽భమ
(𝑒ఈାఉ஽భାఊ஽భమ)ଶ
− 𝐷ଶଶ
𝑒ఈାఉ஽మାఊ஽మమ
(𝑒ఈାఉ஽మାఊ஽మమ)ଶ
൱ 
Then, using the delta method, we have that: 
𝑓(𝛼, 𝛽, 𝛾) = 𝜋(𝐷ଵ) − 𝜋(𝐷ଶ)
ௗ
→ 𝑁 ቀ  𝑓൫𝛼ො, 𝛽መ, 𝛾ො൯ ,    𝑱𝒇൫𝛼ො, 𝛽መ, 𝛾ො൯𝛀 𝑱𝒇൫𝛼ො, 𝛽መ, 𝛾ො൯
்  ቁ 
